https://www.bioworld.com/rss en-us New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria. http://www.bioworld.com/articles/733043 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733043-apac-roundup-nmpa-nods-lupins-16m-spinoff-car-t-data-more Globe isolated on white background with focus on Asia and Australia In a rare event for the European biotech sector, Dutch/Belgian immunology specialist Argenx SE is to acquire a U.S. counterpart, Forte Biosciences Inc., in an all cash deal valued at $2.2 billion. The price of $77 per share is a premium of about 86% to Forte’s volume-weighted average price since it reported positive phase Ib data for the lead program FB-102 in vitiligo on July 9. http://www.bioworld.com/articles/732913 Mon, 27 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732913-argenx-expands-immune-pipeline-in-22b-cash-acquisition-of-forte Antibodies artwork New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria. http://www.bioworld.com/articles/732867 Fri, 24 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732867-apac-roundup-nmpa-nods-lupins-16m-spinoff-car-t-data-more Globe isolated on white background with focus on Asia and Australia Dassault Systèmes agreed to buy Arisglobal for up to $2 billion as it strengthens its position in the life sciences sector, advancing its ambition to create a unified AI intelligence platform for the industry where datasets are currently fragmented. The deal brings together Arisglobal’s AI-powered safety and regulatory intelligence platform with Dassault’s own position in scientific modeling and simulation, to create what the company calls the industry’s first AI platform that unifies real-world evidence with virtual evidence. http://www.bioworld.com/articles/732851 Thu, 23 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732851-dassault-systemes-to-buy-arisglobal-for-up-to-2b Data science concept Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion. BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion.]]> http://www.bioworld.com/articles/732845 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732845-junes-257b-m-and-a-haul-caps-biopharmas-record-breaking-first-half Chess board and pieces, blocks spelling out M&A Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd. and its EGFR inhibitor for lung cancer, as well as Innovent Biologics Inc. and its anti-CD40L antibody for a chronic fibroinflammatory condition. http://www.bioworld.com/articles/732844 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732844-asia-deal-flurry-draws-az-spero-to-1b-dizal-innovent-assets Global deals illustration Hansoh Pharmaceutical Group Co. Ltd. has taken a new step in the evolution of China’s “newco” strategy, combining its newly created U.S. company, Avere Therapeutics Inc., with Nasdaq-listed Nextcure Inc. in a deal designed less to merge pipelines than to create a public vehicle for global development of a China-originated asset. http://www.bioworld.com/articles/732843 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732843-hansoh-takes-newco-route-to-globalize-il-23-asset Glass globe with documents and pen The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution. http://www.bioworld.com/articles/732840 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732840-to-viral-or-not-to-viral-in-vivo-car-t-debates-delivery-tech Red CAR T cell on blue blackground The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution. http://www.bioworld.com/articles/732839 Tue, 21 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732839-to-viral-or-not-to-viral-in-vivo-car-t-debates-delivery-tech Red CAR T cell on blue blackground The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution. http://www.bioworld.com/articles/732736 Mon, 20 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732736-to-viral-or-not-to-viral-in-vivo-car-t-debates-delivery-tech Red CAR T cell on blue blackground On the tail of rumors that Merck & Co. Inc. and others holding stakes in Personalis Inc. might take over the firm, Chicago-based Tempus AI Inc. ended speculation by disclosing its plan to buy the company for $16.25 per share, which amounts to an enterprise value of $1.5 billion net of Tempus’ existing ownership interest. http://www.bioworld.com/articles/732734 Mon, 20 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732734-tempus-finds-time-right-for-15b-personalis-mrd-grab Tempus AI researcher in lab Credit: Tempus AI Inc. Leica Biosystems GmbH, agreed to buy Statlab Medical Products in a move that will strengthen parent company Danaher Corp.'s diagnostics and anatomical pathology portfolio with a broader range of consumables and instruments. Although the financial terms were not disclosed, RBC Capital Markets analyst Dan Leonard reckoned that the deal could be valued at more than $1 billion. http://www.bioworld.com/articles/732725 Fri, 17 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732725-danahers-leica-to-buy-statlab-to-expand-pathology-footprint Microscope and pathology slides Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion. BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion.]]> http://www.bioworld.com/articles/732723 Fri, 17 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732723-junes-257b-m-and-a-haul-caps-biopharmas-record-breaking-first-half Chess board and pieces, blocks spelling out M&A Mirador Therapeutics Inc. has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting anti-C5a antibody with potential to treat ANCA-associated vasculitis. http://www.bioworld.com/articles/732706 Fri, 17 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732706-mirador-licenses-kiras-long-acting-anti-c5a-antibody-kp-301 3D illustration of antibodies Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley Inc. (NASDAQ:ATAI) ended July 16 at $7.15, up $1.79, or 33%, as Wall Street learned that Eli Lilly and Co. is taking over the psychedelics firm for $6.75 per share in cash plus up to $2.50 per share in the form of a contingent value right related to milestones for two Ataibeckley compounds. http://www.bioworld.com/articles/732690 Thu, 16 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732690-atai-dyed-lilly-tees-up-in-psychedelics-finds-38b-fit Silhouette of head and brainwith fractal art Hansoh Pharmaceutical Group Co. Ltd. has taken a new step in the evolution of China’s “newco” strategy, combining its newly created U.S. company, Avere Therapeutics Inc., with Nasdaq-listed Nextcure Inc. in a deal designed less to merge pipelines than to create a public vehicle for global development of a China-originated asset. http://www.bioworld.com/articles/732610 Wed, 15 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732610-hansoh-takes-newco-route-to-globalize-il-23-asset Glass globe with documents and pen Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. http://www.bioworld.com/articles/732665 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732665-astrazeneca-nabs-pde3-4-inhibitor-for-copd-in-21b-sino-deal Red lungs on blue background Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd. and its EGFR inhibitor for lung cancer, as well as Innovent Biologics Inc. and its anti-CD40L antibody for a chronic fibroinflammatory condition. http://www.bioworld.com/articles/732598 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732598-asia-deal-flurry-draws-az-spero-to-1b-dizal-innovent-assets Global deals illustration Edwards Lifesciences Corp. and Genesis Medtech Group Ltd. will pay a total of $12 million in penalties as part of a U.S. FTC settlement resolving allegations that they intentionally structured a deal in which Edwards acquired Genesis’ JC Medical to avoid complying with the notification and waiting period requirements of the Hart-Scott-Rodino Act. http://www.bioworld.com/articles/732531 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732531-med-tech-companies-slapped-with-historic-ftc-penalty Med-tech M&As through the first half (H1) of 2026 reached $75.73 billion in collective value, the highest H1 total since 2022’s $120.4 billion and well above every other year in BioWorld’s records. June contributed $12.21 billion, a rebound from May’s relatively quiet $1.51 billion. BioWorld’s records. June contributed $12.21 billion, a rebound from May’s relatively quiet $1.51 billion. ]]> http://www.bioworld.com/articles/732530 Fri, 10 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732530-danaher-masimo-close-caps-med-techs-strongest-first-half-since-2022 M&A letters over missing puzzle pieces Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. http://www.bioworld.com/articles/732430 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732430-astrazeneca-nabs-pde3-4-inhibitor-for-copd-in-21b-sino-deal Red lungs on blue background Representing the fourth largest biopharma M&A announced in 2026, Vertex Pharmaceuticals Inc. offered $85 per share in cash, or about $10 billion, to buy endocrine specialist Crinetics Pharmaceuticals Inc., adding the acromegaly drug Palsonify and a phase III asset, atumelnant, for congenital adrenocorticotropic hyperplasia (CAH). http://www.bioworld.com/articles/732417 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732417-endocrinology-becomes-vertexs-fifth-pillar-with-10b-crinetics-buy Hand pointing at digital M&A screen Astrazeneca plc has returned to China’s CSPC Pharmaceutical Group Ltd. for another discovery collaboration, this time in a deal worth up to $1.77 billion to use CSPC’s siRNA drug discovery platform and extrahepatic targeted delivery technology to develop small nucleic acid drug candidates. http://www.bioworld.com/articles/732469 Tue, 07 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732469-astrazeneca-returns-to-tap-chinas-cspc-in-17b-discovery-deal Deal illustration Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and more potent class of payload. With the first two programs due to enter clinical development before the end of the year, the Swiss pharma also will pay up to $400 million more in potential milestones. The centerpiece of the deal is London-based Myricx’s N-myristoyltransferase inhibitors, which in preclinical testing have prompted complete and durable tumor regression at well-tolerated doses in a range of solid tumors. http://www.bioworld.com/articles/732468 Tue, 07 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732468-novartis-to-pay-15b-for-myricx-bio-and-its-novel-adc-payloads 3D rendering of antibody drug conjugated with cytotoxic payload Vertex Pharmaceuticals Inc. is buying Crinetics Pharmaceuticals Inc. for $85 per share in cash, which translates to about $10 billion in equity value. Both boards approved the transaction, expected to close in the third quarter of 2026. http://www.bioworld.com/articles/732289 Mon, 06 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732289-vertex-buying-crinetics-for-10b Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and more potent class of payload. With the first two programs due to enter clinical development before the end of the year, the Swiss pharma also will pay up to $400 million more in potential milestones. The centerpiece of the deal is London-based Myricx’s N-myristoyltransferase inhibitors, which in preclinical testing have prompted complete and durable tumor regression at well-tolerated doses in a range of solid tumors. http://www.bioworld.com/articles/732285 Mon, 06 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732285-novartis-to-pay-15b-for-myricx-bio-and-its-novel-adc-payloads 3D rendering of antibody drug conjugated with cytotoxic payload Astrazeneca plc has returned to China’s CSPC Pharmaceutical Group Ltd. for another discovery collaboration, this time in a deal worth up to $1.77 billion to use CSPC’s siRNA drug discovery platform and extrahepatic targeted delivery technology to develop small nucleic acid drug candidates. http://www.bioworld.com/articles/732396 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732396-astrazeneca-returns-to-tap-chinas-cspc-in-17b-discovery-deal Deal illustration Zimmer Biomet Holdings Inc.’s deal to buy Pacira Biosciences Inc.’s Iovera system for up to $140 million and Eurobio Scientific SA’s acquisition of Caredx Inc.’s lab products business for $171.2 million are symptomatic of a broader trend among med-tech and diagnostics companies using targeted acquisitions to strengthen specific areas of their portfolio. http://www.bioworld.com/articles/732261 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732261-cool-move-by-zimmer-part-of-med-techs-tuck-in-deals-trend Handshake icon engraved on metal hexagonal background Ipsen SA announced its second acquisition of the week, saying it will pay €700 million (US$797 million) for Memo Therapeutics AG and its phase III-ready drug potravitug, a treatment for BK virus-associated infections and nephropathy in immune-compromised kidney transplant patients. http://www.bioworld.com/articles/732257 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732257-in-2nd-deal-of-week-ipsen-buys-memos-kidney-transplant-antibody Illustration of antibodies flying around a kidney Nuvectis Pharma Inc.’s shares climbed further after the oncology-focused biotech nabbed select rights to a late-stage complement factor B inhibitor (HSK-39297/NXP-100) and a phase I BRAF inhibitor (HSK-42360/NXP-200) from Haisco Pharmaceutical Group Co. Ltd. for $40 million up front. http://www.bioworld.com/articles/732348 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732348-nuvectis-shares-continue-to-rally-after-146b-haisco-deal Dollar symbol with arrow graph